治疗地理缩的治疗创新:一个有希望的地平线
Eva C de Oliveira Figueiredo1, Claudio Bucolo2, Chiara M Eandi3
1Hôpital Ophtalmique Jules-Gonin, Fondation Asile des Aveugles, Lausanne, Switzerland.
Current opinion in pharmacology
|September 7, 2024
概括
对地理缩的新疗法,一种与年龄相关的黄斑变性晚期形式,显示出有希望. 这些包括抗补剂,基因和基于细胞的疗法,以对抗视力丧失.
科学领域:
- 眼科医生 眼科 眼科
- 再生医学是一种再生医学.
- 遗传学 是一个遗传学.
背景情况:
- 地理缩 (GA) 是与年龄相关的黄斑变性 (AMD) 的晚期阶段.
- 由于视网膜色素上皮损伤,GA导致严重的,不可逆转的视力丧失.
- 复杂的GA病理生理学需要不同的治疗方法.
研究的目的:
- 审查地理缩的有希望的治疗策略.
- 为了突出抗补剂,基因和基于细胞的GA治疗方法的进步.
- 讨论人工智能在诊断GA方面的作用.
主要方法:
- 关于GA治疗的当前文献的审查.
- 对新兴疗法的临床前和临床数据的分析.
- 讨论各种治疗方式的作用机制.
主要成果:
- 针对C3和C5因子的抗补剂疗法显示出降低炎症和GA进展的潜力.
- 基因疗法正在开发中,以解决潜在的遗传缺陷,并可能逆转疾病的进展.
- 基于细胞的疗法在替换受损的视网膜细胞方面显示出令人鼓舞的早期结果.
结论:
- 对于地理缩而言,多种有前途的治疗途径正在出现.
- 抗补剂,基因和基于细胞的疗法代表了进步的关键领域.
- 进一步的研究对于将这些有前途的治疗方法转化为AMD患者的临床实践至关重要.
相关概念视频
Open Angle Glaucoma: Treatment
408
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
408
Angle Closure Glaucoma: Treatment
454
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
454
Alzheimer's Disease: Treatment
170
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
170


